Transcutaneous Electrical Nerve Stimulator to Improve Blood Glucose Control in Patients With Type 2 Diabetes Mellitus

NACompletedINTERVENTIONAL
Enrollment

160

Participants

Timeline

Start Date

April 10, 2017

Primary Completion Date

July 15, 2020

Study Completion Date

July 31, 2020

Conditions
Type 2 Diabetes Mellitus
Interventions
DEVICE

Transcutaneous Electrical Nerve Stimulator (DW1330)

The 20 weeks of treatment of the DW1330 device, all the patients enrolled should perform 1 treatment within 1 hour after dinner 5 days a week.

DEVICE

Sham DW1330 device

The Sham DW1330 device will be masked by the same appearance as the study device (DW1330). The usage of time and location of Sham DW1330 device will be completely the same with study device (DW1330). However, the electronic model, including the frequency and time consistence of electronic stimulation are different between the Sham DW1330 device and the study device (DW1330). The 20 weeks of treatment of the DW1330 device, all the patients enrolled should perform 1 treatment within 1 hour after dinner 5 days a week.

Trial Locations (6)

100

National Taiwan University Hospital, Taipei

220

Far Eastern Memorial Hospital, New Taipei City

600

Chia-Yi Christian Hospital, Chiayi City

704

National Cheng Kung University Hospital, Tainan City

710

Chi Mei Hospital, Tainan City

23561

Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare, New Taipei City

All Listed Sponsors
lead

Taiwan Resonant Waves Research Corporation

INDUSTRY

NCT03102424 - Transcutaneous Electrical Nerve Stimulator to Improve Blood Glucose Control in Patients With Type 2 Diabetes Mellitus | Biotech Hunter | Biotech Hunter